BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Blanco I, Diego I. α1-antitrypsin PI*SZ genotype: a SERPINA1 deficiency haplotype with uncertain clinical and therapeutic implications. Eur Respir J 2020;55:2000713. [PMID: 32554776 DOI: 10.1183/13993003.00713-2020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Sucena M, Gomes J, Guimarães C, Miravitlles M. Implementation of European Alpha-1 Research Collaboration (EARCO) in Portugal: the future starts now. Pulmonology 2020;26:181-3. [DOI: 10.1016/j.pulmoe.2020.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Pye A, Khan S, Whitehouse T, Turner AM. Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiency. Expert Review of Precision Medicine and Drug Development 2021;6:65-78. [DOI: 10.1080/23808993.2021.1862648] [Reference Citation Analysis]
4 Barrecheguren M, O'Hara K, Wilkens M, Boyd J, Kolda E, Lara B, Chorostowska-Wynimko J, Ferrarotti I, Chlumský J, Clarenbach C, Greulich T, Miravitlles M, Sucena M. Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration. ERJ Open Res 2020;6:00523-2020. [PMID: 33447613 DOI: 10.1183/23120541.00523-2020] [Reference Citation Analysis]
5 Schouten IGM, Kasteleyn MJ, Tsonaka R, Bals R, Turner AC, Ferrarotti I, Corsico AG, Lara B, Miravitlles M, Stockley RA, Stolk J. Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database. ERJ Open Res 2021;7:00194-2021. [PMID: 34435030 DOI: 10.1183/23120541.00194-2021] [Reference Citation Analysis]
6 Barrecheguren M, Torres-Duran M, Casas-Maldonado F, Miravitlles M. Spanish Implementation of the New International Alpha-1 Anitrypsin Deficiency International Registry: The European Alpha-1 Research Collaboration (EARCO). Arch Bronconeumol (Engl Ed) 2021;57:81-2. [PMID: 32197815 DOI: 10.1016/j.arbres.2020.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Miravitlles M, Herepath M, Priyendu A, Sharma S, Vilchez T, Vit O, Haensel M, Lepage V, Gens H, Greulich T. Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews. Eur Respir Rev 2022;31:210262. [PMID: 35321931 DOI: 10.1183/16000617.0262-2021] [Reference Citation Analysis]
8 Miravitlles M, Nuñez A, Torres-durán M, Casas-maldonado F, Rodríguez-hermosa JL, López-campos JL, Calle M, Rodríguez E, Esquinas C, Barrecheguren M. The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2020;17:346-54. [DOI: 10.1080/15412555.2020.1795824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]